As part of the deal, UCB will receive the world-wide exclusive license to develop and commercialize Neuropore’s new small molecule NPT200-11in all indications. NPT200-11 that targets pathogenic alpha-synuclein
ATB-346 targets the need for a safer non-steroidal anti-inflammatory drug (NSAID) for chronic pain and inflammation. According to the company, safety concerns centered on the finding of significant
Of the total amount, $5.65m will be spent on Coldstream facility on the Research Park Campus of the University, while the remaining will be used to acquire the
The combination has been approved with or without ribavirin (RBV) for these patients, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver
NBI-77860 is a potent, selective non-peptide CRF receptor antagonist as showed in a range of in vitro/in vivo assays and human clinical trials. Blockade of CRF receptors at
The IMI grant will be used to accelerate the development and testing of JNJ’s vaccine regimen through a newly formed consortium that includes Janssen, the London School of
The Phase II results showed that mipsagargin appears to be effective and is well-tolerated by HCC patients. Mipsagargin targets the enzyme prostate-specific membrane antigen (PSMA), which is highly
The company said that advancement to the predictive biomarker expansion stage triggered a $5m milestone from its partner GlaxoSmithKline (GSK). The expansion stage of the anti-Notch1 Phase Ia
The deal is expected to strengthen Sanofi’s manufacturing capacity to support upcoming product launches. Currently, 72% of Sanofi’s research and development (R&D) projects are in biologics, nearly half
The randomized, double-blind, placebo-controlled Phase II trial was designed to evaluate the efficacy and safety of TNX-102 SL in people with military-related PTSD and related conditions. Tonix president
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.